Starpharma Strengthens Financial Position as FY26 Revenue Accelerates
Source: Kapitales Research
Starpharma (ASX: SPL) delivered a stronger FY26 financial performance, with revenue rising 145% to AU$12.05 million from AU$4.91 million in FY25. Growth was primarily supported by an AU$8.34 million upfront payment under its collaboration and licence agreement with Genentech, alongside contributions from product sales, royalties, licensing and research activities. The annual loss narrowed 25% to AU$7.47 million, reflecting improved revenue despite higher research investment.The company continued advancing its dendrimer-based oncology portfolio, particularly the DEP® HER2-Lutetium radiopharmaceutical program and other next-generation DEP® candidates. Research and product development expenditure increased to AU$11.15 million, demonstrating continued commitment to pipeline development.Starpharma ended FY26 with AU$11.0 million in cash and subsequently raised net proceeds of AU$30 million through an Entitlement Offer, strengthening liquidity and extending its expected funding runway into FY28.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Starpharma Strengthens Financial Position as FY26 Revenue Accelerates
Starpharma (ASX: SPL) delivered a stronger FY26 financial performance, with revenue rising 145% to AU$12.05 million from AU$4.91 million in FY25. Growth was primarily supported by an AU$8.34 million upfront payment under its collaboration and licence agreement with Genentech, alongside contributions from product sales, royalties, licensing and research activities. The annual loss narrowed 25% to AU$7.47 million, reflecting improved revenue despite higher research investment.The company continued advancing its dendrimer-based oncology portfolio, particularly the DEP® HER2-Lutetium radiopharmaceutical program and other next-generation DEP® candidates. Research and product development expenditure increased to AU$11.15 million, demonstrating continued commitment to pipeline development.Starpharma ended FY26 with AU$11.0 million in cash and subsequently raised net proceeds of AU$30 million through an Entitlement Offer, strengthening liquidity and extending its expected funding runway into FY28.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au